Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CHEK 
Check Cap Ltd (CHEK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/26/2025: CHEK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.42% | Avg. Invested days 50 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.42M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 1 | Beta 0.46 | 52 Weeks Range 0.56 - 3.13 | Updated Date 11/28/2025 |
52 Weeks Range 0.56 - 3.13 | Updated Date 11/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.27 |
Earnings Date
Report Date 2025-11-24 | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.58% | Return on Equity (TTM) -226.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9349467 | Price to Sales(TTM) - |
Enterprise Value 9349467 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.74 | Shares Outstanding 5850906 | Shares Floating 4389584 |
Shares Outstanding 5850906 | Shares Floating 4389584 | ||
Percent Insiders 20.82 | Percent Institutions 0.66 |
Upturn AI SWOT
Check Cap Ltd
Company Overview
History and Background
Check Cap Ltd. is an Israeli-based company focused on the development of ingestible medical imaging capsules. It was founded to improve colon cancer screening using minimally invasive technology.
Core Business Areas
- Medical Imaging: Developing and commercializing C-Scan, a preparation-free ingestible capsule for colon screening.
Leadership and Structure
Check Cap Ltd. has a board of directors and an executive management team. Leadership includes a CEO, CFO, and heads of R&D and Operations.
Top Products and Market Share
Key Offerings
- C-Scan: C-Scan is Check Cap's primary product. It is an ingestible capsule that uses low-dose X-ray technology to generate 3D images of the colon without the need for bowel preparation. The competitors are traditional colonoscopies from Boston Scientific (BSX) and Exact Sciences (EXAS) (Cologuard). Market share data is still emerging, dependent on regulatory approvals and adoption rates, however analysts estimate a potential share of 1-3% in the near future.
Market Dynamics
Industry Overview
The medical device industry is experiencing growth, especially in minimally invasive diagnostics. Colon cancer screening remains a critical area with unmet needs.
Positioning
Check Cap positions itself as offering a convenient and preparation-free alternative to traditional colonoscopies.
Total Addressable Market (TAM)
The colon cancer screening market is estimated to be worth billions of dollars annually. C-Scan aims to capture a segment of this market by addressing patient reluctance to undergo traditional screening methods. Estimates predict the total addressable market for the next generation, patient centric colon cancer screening to be $5 billion with 10% addressable by Check Cap's technology.
Upturn SWOT Analysis
Strengths
- Preparation-free colon screening
- Minimally invasive procedure
- Potential for increased patient compliance
- Proprietary X-ray technology
Weaknesses
- Limited clinical data compared to colonoscopy
- Dependence on regulatory approvals
- Requires specialized reading software and infrastructure
- Low sales numbers
Opportunities
- Partnerships with healthcare providers and insurance companies
- Expansion into new markets
- Development of next-generation imaging technologies
- Increasing awareness of colon cancer screening benefits
Threats
- Competition from existing colonoscopy methods
- Regulatory hurdles
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- BSX
- EXAS
Competitive Landscape
Check Cap's competitive advantage lies in its preparation-free and minimally invasive approach, but it faces challenges due to market incumbents.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, given Check Cap's development stage.
Future Projections: Future growth is dependent on regulatory approvals and commercialization success of C-Scan.
Recent Initiatives: Recent initiatives include clinical trials and regulatory submissions for C-Scan.
Summary
Check Cap Ltd is a development-stage company with promising technology for colon cancer screening. Its potential lies in offering a more convenient alternative to traditional colonoscopies. Success hinges on regulatory approvals, commercialization, and competition from established players. It faces significant execution risks and financial constraints.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in pre-revenue companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Check Cap Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-02-19 | Interim CEO & Chairman of the Board Mr. David Lontini | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees - | Website https://check-cap.com |
Full time employees - | Website https://check-cap.com | ||
Check-Cap Ltd., a clinical stage medical diagnostics company, focuses on capsule-based screening technology products. The company was incorporated in 2004 and is based in Isfiya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.